IL174508A0 - New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 - Google Patents

New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1

Info

Publication number
IL174508A0
IL174508A0 IL174508A IL17450806A IL174508A0 IL 174508 A0 IL174508 A0 IL 174508A0 IL 174508 A IL174508 A IL 174508A IL 17450806 A IL17450806 A IL 17450806A IL 174508 A0 IL174508 A0 IL 174508A0
Authority
IL
Israel
Prior art keywords
cx3cr1
thiazolo
pyrimidines
esp
amino
Prior art date
Application number
IL174508A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Nordvall Gunnar
Rein Tobias
Sohn Daniel
Zemribo Ronald
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0302667A external-priority patent/SE0302667D0/xx
Priority claimed from SE0302666A external-priority patent/SE0302666D0/xx
Application filed by Astrazeneca Ab, Nordvall Gunnar, Rein Tobias, Sohn Daniel, Zemribo Ronald filed Critical Astrazeneca Ab
Publication of IL174508A0 publication Critical patent/IL174508A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL174508A 2003-10-07 2006-03-23 New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 IL174508A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0302667A SE0302667D0 (sv) 2003-10-07 2003-10-07 Novel Compounds
SE0302666A SE0302666D0 (sv) 2003-10-07 2003-10-07 Novel Compounds
PCT/SE2004/001421 WO2005033115A1 (en) 2003-10-07 2004-10-05 New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1

Publications (1)

Publication Number Publication Date
IL174508A0 true IL174508A0 (en) 2006-08-01

Family

ID=34425473

Family Applications (1)

Application Number Title Priority Date Filing Date
IL174508A IL174508A0 (en) 2003-10-07 2006-03-23 New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1

Country Status (11)

Country Link
US (1) US20070142386A1 (en:Method)
EP (1) EP1675862A1 (en:Method)
JP (1) JP2007507494A (en:Method)
KR (1) KR20060120014A (en:Method)
AU (1) AU2004278276B2 (en:Method)
BR (1) BRPI0415050A (en:Method)
CA (1) CA2541533A1 (en:Method)
IL (1) IL174508A0 (en:Method)
MX (1) MXPA06003792A (en:Method)
NO (1) NO20062061L (en:Method)
WO (1) WO2005033115A1 (en:Method)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US8518401B1 (en) 2004-10-29 2013-08-27 Eisai R&D Management Co., Ltd. Treating inflammatory diseases with antibodies that inhibit fractalkine-CXCR1 interaction
US20090239882A1 (en) * 2004-12-17 2009-09-24 Astrazeneca Ab Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) * 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
WO2008005303A2 (en) * 2006-06-30 2008-01-10 Janssen Pharmaceutica N.V. Thiazolopyrimidine modulators of trpv1
TW200820973A (en) * 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
RU2437889C2 (ru) 2006-09-29 2011-12-27 Астразенека Аб НОВЫЕ 5,7-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2-(3Н)-АМИНА И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
PE20091102A1 (es) 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
WO2009079000A1 (en) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolopyrimidine modulators of trpv1
DK2262777T3 (en) 2008-03-07 2016-05-17 Acraf 1-benzyl-3-hydroxymetylindazolderivater and their use in the treatment of diseases based on the expression of MCP-1 and CX3CR1
PL2254870T3 (pl) * 2008-03-07 2016-07-29 Acraf Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1
EA018976B1 (ru) 2008-03-07 2013-12-30 Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии мср-1, cx3cr1 и p40
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
EP2648754A4 (en) * 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHOD OF INHIBITING CANCER METASTASES
TWI543975B (zh) * 2011-09-13 2016-08-01 Eisai R&D Man Co Ltd Pyrrolidin-3-yl acetic acid derivatives
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
CA2900926A1 (en) * 2013-03-12 2014-09-18 Eisai R&D Management Co., Ltd. Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof
WO2014142086A1 (ja) * 2013-03-13 2014-09-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピロリジン－３－イル酢酸誘導体およびピペリジン－３－イル酢酸誘導体
WO2018204370A1 (en) 2017-05-02 2018-11-08 Drexel University Cx3cr1 small molecule antagonists, and methods using same
GB201811169D0 (en) * 2018-07-06 2018-08-29 Kancera Ab New compounds
CR20250196A (es) 2022-10-19 2025-11-21 Astrazeneca Ab 1,3,5-triazinas 2,4,6-trisustituidas como moduladores de cx3cr1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
SE0101082D0 (sv) * 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
SE0101322D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
JP2007507494A (ja) 2007-03-29
BRPI0415050A (pt) 2006-11-28
WO2005033115A1 (en) 2005-04-14
NO20062061L (no) 2006-07-03
US20070142386A1 (en) 2007-06-21
CA2541533A1 (en) 2005-04-14
AU2004278276B2 (en) 2007-10-18
KR20060120014A (ko) 2006-11-24
EP1675862A1 (en) 2006-07-05
AU2004278276A1 (en) 2005-04-14
MXPA06003792A (es) 2006-06-14

Similar Documents

Publication Publication Date Title
IL174508A0 (en) New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
AP2006003566A0 (en) Muscarinic Acetycholine receptor antagonists.
IL182099A0 (en) Piperidinylamino-thieno[2,3-d] pyrimidine compounds
IL182090A0 (en) 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
AP2227A (en) 5,7-diaminopyrazolo [4,3-d]pyrimidines with PDE-5 inhibiting activity.
IL183706A0 (en) 2,4(4,6) pyrimidine derivatives
IL186089A0 (en) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as cgrp antagonists
IS8474A (is) Pýridó[2,3-d]pýrimidín-2,4-díamín sem PDE 2 latar
SMP200600024B (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina
SI1869056T1 (sl) Novi 5-substituirani 7-amino-(1,3)tiazolo(4,5-d) pirimidinski derivati
ZA200610666B (en) Piperidine derivatives as NK, antagonists
AP2157A (en) 2-substituted pyrimidines.
EP1631559A4 (en) IL-8 SB / SB RECEPTOR ANTAGONISTS
ATE325117T1 (de) 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten
IL178622A0 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
AP2005003196A0 (en) Bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor.
PL375263A1 (en) 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists
SG131946A1 (en) Ccr3 receptor antagonists
IL169318A0 (en) Pyrimidines, methods for the production thereof, and use thereof
HK1089760A (en) New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
AP2006003496A0 (en) 2-Substituted pyrimidines.
MXPA03009930A (es) Antagonistas del receptor del factor liberador de corticotropina.
IL173347A0 (en) 7-SUBSTITUTED 3-NITRO-PYRAZOLO[1,5-a] PYRIMIDINES
HK1092136A (en) New piperidinylamino-thieno 2,3-d pyrimidine compounds